Revive Therapeutics Ltd (RVVTF)

$0.02 +0.00 (8.11%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 32,000
Avg Vol 132,132
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 63%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which i...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 888-901-0036
Fax: 905-248-3355
Address:
The Canadian Venture Building, 82 Richmond Street East, Toronto, Canada
BigWilly12
BigWilly12 Aug. 31 at 9:26 PM
$RVVTF investor deck updated https://revivethera.com/wp-content/uploads/2026/08/RVV_Investor_Presentation_Q3_2026.pdf
1 · Reply
LifesGood
LifesGood Aug. 31 at 6:20 PM
$RVVTF For Revive Therapeutics RVVTF, the next major expected catalyst and news flow centers heavily on its biodefense pipeline updates and upcoming operational milestones:Q4 2026 Confirmatory Studies: The primary operational catalyst on the horizon is the launch of confirmatory Defense Research and Development Canada (DRDC) animal-model studies scheduled for Q4 2026. These studies will follow up on positive data regarding Bucillamine as a potential treatment/countermeasure for nerve-agent exposure.Government Funding & Partnership Updates: Following its strategic update outlining a pivot toward biodefense and pandemic preparedness, investors are tracking any announcements regarding government-backed funding, grants, or development partnerships in Canada and the U.S.Private Placement Closings: The company has been working through private placement tranches to raise capital, meaning news regarding final closing filings or additional financing updates could drop periodically.
0 · Reply
LifesGood
LifesGood Aug. 31 at 4:18 PM
$RVVTF
0 · Reply
sica1983
sica1983 Aug. 31 at 3:01 PM
$RVVTF no volume at all, 0 traded…interesting 🧐
1 · Reply
BobWarner99
BobWarner99 Aug. 30 at 5:15 PM
$RVVTF No Pump but a Question. Are the pieces already in place for RVVTF to sign a revenue generating contract before 2026 year's end? Is MF pulling everyone's leg to sell shares or could he deliver big in 2026? From the 8/12/2026 PR - Revive Therapeutics Reports Positive Results From DRDC Bucillamine Nerve-Agent Research Study "The DRDC research study provides a scientific basis for continuing to evaluate bucillamine in combination with established treatments for nerve-agent exposure," said Michael Frank, Chief Executive Officer of Revive. "Bucillamine demonstrated preservation of the measured GABA receptor endpoint comparable to NAC, while pulmonary hemorrhage observed in the NAC-treated group was not observed in the bucillamine-treated group. These findings support our broader objective of evaluating bucillamine's potential role in biodefence and pandemic preparedness, and we intend to explore further related opportunities with government, defence, and other strategic organizations."
0 · Reply
BobWarner99
BobWarner99 Aug. 29 at 2:23 PM
$RVVTF If miracles happens and MF comes through with a possible multi thousands dollars or multi million dollars deal. Does RVVTF already have a partner to handle commercial production in place already?? MF if you wanna drop a revenue generating contract in September 2026 we won't be upset. 🤔 https://www.globenewswire.com/news-release/2023/12/18/2797682/0/en/revive-therapeutics-collaborates-with-attwill-medical-solutions-for-the-clinical-and-commercial-development-of-a-novel-lyophilized-formulation-of-bucillamine.html
1 · Reply
BobWarner99
BobWarner99 Aug. 28 at 9:43 AM
$RVVTF Sorry but this is crazy AF. It looks like MF has paid off the "$61,061 in outstanding trade payables owing to two arm's length creditors of the Company (the "Debt Settlement").". The is based on the adjusted outstanding share count. The total number of outstanding shares went up exactly by that amount of the debt(1,221,516). Why didn't he just take this out of his salary? Maybe even sell some of his cigars or robes on Ebay? The number of outstanding shares is still not bad considering how fast this seems to move when volume comes in....but still. Looks like).
2 · Reply
BobWarner99
BobWarner99 Aug. 27 at 8:28 PM
$RVVTF Maybe this is a huge nothing burger. Maybe it happened before and I didn't notice. When I do a search of Revive Therapeutics in Google, it includes their phone number. Again maybe this a huge nothing burger. 😐
2 · Reply
JTM67
JTM67 Aug. 27 at 4:00 AM
$RVVTF Agree as although RVVTF owns the patent rights to Bucillimine: They don't have the funding - manufacturing / production capacity - distribution schematics - employees or know how, etc to take this Company to the next level assuming future contracts start coming our way. They need to line up Partnerships now -- being prepared to throw the "on switch" per the first batch of orders... Think about this: MFrank is having "challenges" currently raising $1M per the private placenent over how long now period of time ? So how in the Hell is MFrank going to fill a batch of DRDC orders on his own ? Let's F'n Gooooooo ! 🤑
1 · Reply
Bull80
Bull80 Aug. 27 at 12:25 AM
$RVVTF Think about it—maybe they are getting all the long-term relationships on board before something big happens. Hopefully, but looking at the indicators: Creditors converted their loans into shares at $0.05 when the stock was trading at around $0.018. They could have asked for their money back and potentially bought more than twice the number of shares in the open market. The fact that they chose to convert at $0.05 makes me think management must have told them something that convinced them to take this option. The same applies to employees who received options to exercise at $0.05 when the stock was trading at around $0.018. Based on this information, would you say the trend is bullish or bearish?
2 · Reply
Latest News on RVVTF
No data available.
BigWilly12
BigWilly12 Aug. 31 at 9:26 PM
$RVVTF investor deck updated https://revivethera.com/wp-content/uploads/2026/08/RVV_Investor_Presentation_Q3_2026.pdf
1 · Reply
LifesGood
LifesGood Aug. 31 at 6:20 PM
$RVVTF For Revive Therapeutics RVVTF, the next major expected catalyst and news flow centers heavily on its biodefense pipeline updates and upcoming operational milestones:Q4 2026 Confirmatory Studies: The primary operational catalyst on the horizon is the launch of confirmatory Defense Research and Development Canada (DRDC) animal-model studies scheduled for Q4 2026. These studies will follow up on positive data regarding Bucillamine as a potential treatment/countermeasure for nerve-agent exposure.Government Funding & Partnership Updates: Following its strategic update outlining a pivot toward biodefense and pandemic preparedness, investors are tracking any announcements regarding government-backed funding, grants, or development partnerships in Canada and the U.S.Private Placement Closings: The company has been working through private placement tranches to raise capital, meaning news regarding final closing filings or additional financing updates could drop periodically.
0 · Reply
LifesGood
LifesGood Aug. 31 at 4:18 PM
$RVVTF
0 · Reply
sica1983
sica1983 Aug. 31 at 3:01 PM
$RVVTF no volume at all, 0 traded…interesting 🧐
1 · Reply
BobWarner99
BobWarner99 Aug. 30 at 5:15 PM
$RVVTF No Pump but a Question. Are the pieces already in place for RVVTF to sign a revenue generating contract before 2026 year's end? Is MF pulling everyone's leg to sell shares or could he deliver big in 2026? From the 8/12/2026 PR - Revive Therapeutics Reports Positive Results From DRDC Bucillamine Nerve-Agent Research Study "The DRDC research study provides a scientific basis for continuing to evaluate bucillamine in combination with established treatments for nerve-agent exposure," said Michael Frank, Chief Executive Officer of Revive. "Bucillamine demonstrated preservation of the measured GABA receptor endpoint comparable to NAC, while pulmonary hemorrhage observed in the NAC-treated group was not observed in the bucillamine-treated group. These findings support our broader objective of evaluating bucillamine's potential role in biodefence and pandemic preparedness, and we intend to explore further related opportunities with government, defence, and other strategic organizations."
0 · Reply
BobWarner99
BobWarner99 Aug. 29 at 2:23 PM
$RVVTF If miracles happens and MF comes through with a possible multi thousands dollars or multi million dollars deal. Does RVVTF already have a partner to handle commercial production in place already?? MF if you wanna drop a revenue generating contract in September 2026 we won't be upset. 🤔 https://www.globenewswire.com/news-release/2023/12/18/2797682/0/en/revive-therapeutics-collaborates-with-attwill-medical-solutions-for-the-clinical-and-commercial-development-of-a-novel-lyophilized-formulation-of-bucillamine.html
1 · Reply
BobWarner99
BobWarner99 Aug. 28 at 9:43 AM
$RVVTF Sorry but this is crazy AF. It looks like MF has paid off the "$61,061 in outstanding trade payables owing to two arm's length creditors of the Company (the "Debt Settlement").". The is based on the adjusted outstanding share count. The total number of outstanding shares went up exactly by that amount of the debt(1,221,516). Why didn't he just take this out of his salary? Maybe even sell some of his cigars or robes on Ebay? The number of outstanding shares is still not bad considering how fast this seems to move when volume comes in....but still. Looks like).
2 · Reply
BobWarner99
BobWarner99 Aug. 27 at 8:28 PM
$RVVTF Maybe this is a huge nothing burger. Maybe it happened before and I didn't notice. When I do a search of Revive Therapeutics in Google, it includes their phone number. Again maybe this a huge nothing burger. 😐
2 · Reply
JTM67
JTM67 Aug. 27 at 4:00 AM
$RVVTF Agree as although RVVTF owns the patent rights to Bucillimine: They don't have the funding - manufacturing / production capacity - distribution schematics - employees or know how, etc to take this Company to the next level assuming future contracts start coming our way. They need to line up Partnerships now -- being prepared to throw the "on switch" per the first batch of orders... Think about this: MFrank is having "challenges" currently raising $1M per the private placenent over how long now period of time ? So how in the Hell is MFrank going to fill a batch of DRDC orders on his own ? Let's F'n Gooooooo ! 🤑
1 · Reply
Bull80
Bull80 Aug. 27 at 12:25 AM
$RVVTF Think about it—maybe they are getting all the long-term relationships on board before something big happens. Hopefully, but looking at the indicators: Creditors converted their loans into shares at $0.05 when the stock was trading at around $0.018. They could have asked for their money back and potentially bought more than twice the number of shares in the open market. The fact that they chose to convert at $0.05 makes me think management must have told them something that convinced them to take this option. The same applies to employees who received options to exercise at $0.05 when the stock was trading at around $0.018. Based on this information, would you say the trend is bullish or bearish?
2 · Reply
sica1983
sica1983 Aug. 26 at 1:47 AM
$RVVTF volume picking up these last few days/weeks, someone is sitting at the bid and absorbing shares..I think someone is trying to build a decent position
0 · Reply
BigWilly12
BigWilly12 Aug. 25 at 10:48 PM
$RVVTF interesting trading today on both sides of the border
1 · Reply
BobWarner99
BobWarner99 Aug. 25 at 8:34 PM
$RVVTF In my opinion the Market is looking for a Press Release with some of the following verbiage.... - $ Million dollars, revenue, contract, deal, partnership etc - Military, NATO, strategic - Non Dilutive financing - Current financials - Recurring revenue We'll see when or if we even see a hypothetical, mythical type of Press Release like this before the year of 2026 closes out.
0 · Reply
Mitchz11
Mitchz11 Aug. 25 at 4:32 PM
$RVVTF the waiting sucks. No way around it. BUT we would all be in a much worse spot if news came out negative about the trial. So our lottery ticket is still alive and kicking!! We are getting there! (Very slowly and unsurely) GLTA!!!
2 · Reply
BigWilly12
BigWilly12 Aug. 24 at 7:29 PM
$RVVTF really surprised by the trading They’re doing confirmation studies in Q4 We got a positive update from the DRDC The company is well positioned for future growth What did I miss?
4 · Reply
RichieOFlaherty
RichieOFlaherty Aug. 24 at 3:10 PM
$RVVTF I hear the current trade war between the United States and Canada, is actually based on a rift between who will get more bucillamine. The US wants trillions worth. Canada only wants to sell billions. Meanwhile, MF is plotting a way to fuck it all up!!!
1 · Reply
Dirtymartini66
Dirtymartini66 Aug. 24 at 2:19 PM
$RVVTF GREAT DAY TO ADD!
0 · Reply
Comonbaby
Comonbaby Aug. 24 at 11:14 AM
$RVVTF happy monday GLTA
0 · Reply
Jaymz46
Jaymz46 Aug. 23 at 10:42 PM
$RVVTF So are we finally going to get some buying pressure tomorrow or what?
1 · Reply
JTM67
JTM67 Aug. 21 at 4:45 PM
$RVVTF Which one of you RVVTF'ers got on the "bad" side of the Maket Maker / Maker's ? These guys are brutal...
1 · Reply
LifesGood
LifesGood Aug. 21 at 2:25 PM
$RVVTF liquidation around .02-.03 when it pass that it'll be sky's the limit
0 · Reply
LifesGood
LifesGood Aug. 21 at 12:11 AM
$RVVTF might be the reversal here, m I may put a 100k buy limit
0 · Reply